Applications of ellagic acid in preparation of immunomodulatory medicines for treatment of neuromyelitis optica or immune rejection after skin transplantation
US11944601B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Feb 24, 2022 |
| Grant date | Apr 2, 2024 |
| Priority date | — |
| Expiry date | Feb 24, 2042 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P37/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
An application of ellagic acid and a metabolic derivative urolithin compound thereof in preparation of an immunomodulatory medicine is provided. Classical animal models of autoimmunity and immunoregulation, such as experimental autoimmune encephalomyelitis, neuromyelitis optica mouse model, ulcerative colitis, and skin transplantation, are used as examples to conduct experiments from various aspects and perspectives, such as neurological function scores, histopathological changes of lesions, inflammatory factor expression, and pro-inflammatory cell numbers. The experiments demonstrate that ellagic acid and its metabolic derivatives significantly improved experimental autoimmune encephalomyelitis recovery and inhibited the infiltration of inflammatory cells into CNS, ameliorated experimental colitis severity and restored length of colon, reduced NMO-IgG-induced brain damage and prevented astrocyte loss and demyelination, as well as suppressed graft rejection and upregulated a proportion of regulatory T cells in order to enhance immune tolerance. Therefore, EA and its metabolic derivatives have high clinical application value and development prospect.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.